LibiGel (BioSante Pharma) fails two Phase III trials for Female Sexual Dysfunction

Results from two Phase III studies of LibiGel (testosterone gel)from BioSante Pharmaceuticals, being BLOOM-1 and BLOOM-2 studies for Hypoactive Sexual Desire Disorder in postmenopausal women did not meet the co-primary or secondary endpoints. BioSante continues to conduct the Phase III LibiGel safety study, a randomized, double-blind, placebo-controlled, multi-center, cardiovascular events and breast cancer study that has completed enrollment of 3,656 women and has accrued over 5,100 women-years of exposure, to date.